|
Sign In to gain access to subscriptions and/or personal tools.
|
Pharmacogenetics to Predict Drug-Related Adverse Events
David A. Hosford
Department of Genetics Research, david.hosford{at}gsk.com
Eric H. Lai
Department of Genetics Research
John H. Riley
Department of Genetics Research
Chun-Fang Xu
Department of Genetics Research
Theodore M. Danoff
Department of Clinical Pharmacology and Discovery Medicine
Allen D. Roses
Department of Genetics Research
Identification of reliable markers to predict drug-related adverse events (DRAEs) is an important goal of the pharmaceutical industry and others within the healthcare community. We have used genetic polymorphisms, including the most frequent source of variation (single nucleotide polymorphisms, SNPs) in the human genome, in pharmacogenetic approaches designed to predict DRAEs. Three studies exemplify the principles of using polymorphisms to identify associations in progressively larger genomic regions: polymorphic repeats within the UDP-glucuronysltransferase I (UGT1A1) gene in patients experiencing hyperbilirubinemia after administration of tranilast, an experimental drug to prevent re-stenosis following coronary revascularization; high linkage disequilibrium within the Apolipoprotein E (ApoE) gene in patients with Alzheimer Disease (AD); and the polymorphic variant HLA-B57 in patients with hypersensitivity reaction after administration of abacavir, a nucleoside reverse transcriptase inhibitor for the treatment of HIV. Together, these studies demonstrate in a stepwise manner the feasibility of using pharmacogenetic approaches to predict DRAEs.
Key Words: Pharmacogenetics • adverse drug reaction • drug-related adverse event • single nucleotide polymorphism • Gilbert's syndrome • Tranilast • Apolipoprotein E • Alzheimer's Disease • abacavir • hypersensitivity reaction.
References
- Bosma, P., Chowdhury, J.R., Bakker, C., Gantla, S., de Boer, A., Oostra, B.A., Lindhout, D., Tytgat, G.N., Jansen, P.L., and Oude Elferink, R.P. (1995). The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Eng J Med 333, 1171— 5.[Abstract/Free Full Text]
- Bosma, P., Chowdhury, N.R., Goldhoorn, B.G., Hofker, M.H., Oude Elferink, R.P., Jansen, P.L., and Chowdhury, J.R. (1992). Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 15: 941—7.[Web of Science][Medline]
[Order article via Infotrieve]
- Haramburu, F., Pouyanne, P., Imbs, J.L., Blayac, J.P., and Begaud, B. (2000). Incidence and prevalence of adverse drug reactions. Presse Medicale 29, 111—4.[Web of Science]
- Hetherington, S., Hughes, A.R., Mosteller, M., Shortino, D., Baker, K.L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D.J., Fling, M.E., Stocum, M., Bowman, C., Thurmond, L.M., and Roses, A.D. (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121—2.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G., and Steel, H. (2001). Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23, 1603—14.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lai, E., Riley, J., Purvis, I., and Roses, A. (1998). A 4-Mb high-density single nucleotide polymorphism-based map around ApoE. Genomics 54, 31—8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A.M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., and Christiansen, F.T. (2002). Lancet 359, 727—32.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Melton, L. (2003). On the trail of SNPs. Nature 422, 917—23.[Medline]
[Order article via Infotrieve]
- Rigby, K.D., and Litt, J.C. (2000). Errors in health care management: what do they cost? Qual Health Care 9, 216—21.[Abstract/Free Full Text]
- Roses, A.D. (2002). Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev 1, 541—9.[CrossRef]
- Saunders, A.M., Strittmatter, W.J., Schmechel, D., St George-Hyslop, P.H., Pericak-Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper-MacLachlan, D.R., Alberts, M.J., and Roses, A.D. (1993). Association of apolipoprotein E allele E4 with late-onset familial and sporadic alzheimer disease. Neurology 43, 1467—72.[Abstract/Free Full Text]
- Schenkel, S. (2000). Promoting patient safety and preventing medical error in emergency departments. Acad Emer Med 7, 1204—22.[Web of Science][Medline]
[Order article via Infotrieve]
- Schioler, T., Lipczak, H., Pedersen, B.L., Mogensen, T.C., Bach, K.B., Stockmarr, A., Svenning, A.R., and Frolich, A. (2001). Incidence of adverse events in hospitals. A retrospective study of medical records. U Laeger 163, 5370—8.
- Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., and Roses, A.D. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial alzheimer disease. Proc Natl Acad Sci USA 90, 1977—81.[Abstract/Free Full Text]
- Thomas E.J., Studdert, D.M., Runciman, W.B., Webb, R.K., Sexton, E.J., Wislon, R.M., Gibberd, R.W., Harrison, B.T., and Brennan, T.A. (2000). A comparison of iatrogenic injury studies in australia and the USA. I. Context, methods, casemix, population, patient and hospital characteristics. Int J Qual Health Care 12, 371—8.[Abstract/Free Full Text]
Toxicologic Pathology, Vol. 32, No. 1 suppl,
9-12 (2004)
DOI: 10.1080/01926230490424743
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
